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Improved delivery of ipratropium bromide using
Respimat1 (a new soft mist inhaler) compared with
a conventional metered dose inhaler: cumulative dose
response study in patients with COPD
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Respimat1 (RMT) is a reusable, propellant-free, soft mist inhaler (SMI), a novel device for inhalation therapy. We
conducted a three-period cross-over study to evaluate the safety and ecacy of cumulative doses of ipratropium
bromide inhaled from RMT (Two dose levels) or from a pressurized metered dose inhaler (MDI), in 36 patients
with chronic obstructive pulmonary disease (COPD). The bronchodilator eect of ipratropium bromide was
greater when administered via RMT (10 or 20 mg per pu, given double-blind within device, to total doses of 160 or
320 mg) than via MDI (20 mg per pu, total dose 320 mg). The bronchodilator eects of the 160 and 320 mg doses
delivered via RMT were similar. Cumulative ipratropium bromide doses of 320 mg given via MDI or RMT and
160 mg given via RMT produced similar safety profiles. Between 45 min after the first drug inhalation and 45 min
after the final dose, greater bronchodilatory eect was obtained from half the cumulative dose of ipratropium
(RMT 10 mg per pu) when compared with the MDI (20 mg per pu). Therefore, ipratropium bromide delivered by
RMT is as safe as, and can be more eective than, the MDI on acute administration in patients with COPD.
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Asthma and chronic obstructive pulmonary disease
(COPD) are amongst the commonest of respiratory
disorders, and inhalation has long been regarded as the
most eective and selective route to treat these conditions.
As the drug is targeted to the required site of action,
relatively small doses of drug can achieve a rapid
therapeutic response with minimal systemic absorption,
reducing the risk of adverse reactions. There are various
types of device available for the delivery of inhalation
medications, including metered dose inhalers (MDIs), dry
powder inhalers (DPIs) and nebulizers. Of these, MDIs are
the most commonly used, and have achieved wide patient
acceptability, being portable and easy to use. However,
most MDIs use volatile chlorofluorocarbon (CFC) propel-
lants, which have been banned in an international agree-
ment on the protection of the stratospheric ozone layer, the
Montreal Protocol. At present, the only permitted use of
CFCs is in MDIs, and these will be withdrawn in the next
few years as acceptable alternatives for delivering respira-
tory medicines are introduced.
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propellants (1). Some alternative devices are already
available, including MDIs containing hydrofluoroalkane
propellants (2), and DPIs (3,4). However, each carries both
advantages and disadvantages based on their lung deposi-
tion characteristics, reliability, consistency and ease of use
(5). Another approach was to design a mechanical means of
delivering a drug solution with favourable particle char-
acteristics resembling those produced by ultrasonic or jet
nebulizers, while retaining the convenience and ease of use
of MDIs. The product of this development strategy, RMT,
is a reusable, propellant-free multidose soft mist inhaler
(SMI). The aerosol it produces has a narrow droplet size
distribution, a high proportion of the dose in the fine
particle fraction (mass median diameter 558 mm), and a
particle velocity about one-fifth of that of the spray released
from conventional MDIs (6,7). Small particle size and low
velocity are known to be important for optimal lung
deposition (8), and RMT has demonstrated improved
targeting of the inhaled dose to the lungs in scintigraphic
studies in volunteers (9–15). Furthermore, pilot studies in
patients with asthma or COPD have shown that the clinical
eect of treatments inhaled from RMT is as good or better
than that of the same doses inhaled from conventional
MDIs (16–19).
Ipratropium bromide is an anticholinergic agent widely
used for bronchodilation in COPD patients. The present# 2000 HARCOURT PUBLISHERS LTD
SMI VS. MDI DELIVERY OF IPRATROPIUM BROMIDE 491study was conducted to determine the safety and ecacy of
cumulative doses of ipratropium bromide inhaled from
RMT compared with a conventional MDI, in patients with
COPD.
Methods
PATIENTS
We studied 36 outpatients presenting with stable COPD as
partly defined by the American Thoracic Society (21) as
follows:
(i) age 440 years;
(ii) smoking history of over 10 pack-years;
(iii) baseline forced expiratory volume in 1 sec (FEV1)
65% of the predicted value according to standard
criteria (22);
(iv) FEV1/forced vital capacity (FVC) ratio of 70%.
All 36 patients were ex-smokers, with a mean +SD past
consumption of 49+15 (range 20–80) pack-years. All
patients exhibited stable airway obstruction responsive to
ipratropium bromide, defined as an improvement in
FEV115% within 1 h after inhaling 2620 mg ipratropium
bromide via MDI. Each patient provided written informed
consent, and underwent medical examination to fulfil
inclusion and exclusion criteria, including lung function
assessment, physical examination, haematology, clinical
chemistry and 12-lead ECG. Patients with a history of
asthma, allergic rhinitis or atopy were excluded. Patients
were also excluded if they were pregnant or lactating, had a
recent upper respiratory tract infection (6 weeks prior to
screening visit) or change in pulmonary medications, were
intolerant or hypersensitive to study drugs or excipients, or
if they were receiving chronic oxygen therapy, oral
corticosteroids, b-blockers, antihistamines or cromolyn/
nedocromil sodium. Stable use of inhaled corticosteroids
was permitted. The study was approved by the Hospital
Ethics Committee.
STUDY DESIGN
In a randomized, three-period cross-over design, included
patients received cumulative doses of ipratropium bromide
(Atrovent1, Boehringer Ingelheim) for 1+1+2+4+8
pus inhaled at 50-min intervals from one of three devices
(all from Boehringer Ingelheim):
(i) RMT delivering 10 mg pu71 (RMT-10);
(ii) RMT delivering 20 mg pu71 (RMT-20);
(iii) CFC-containing MDI delivering 20 mg per pu
(MDI-20).
Thus, the total dose was 320 mg on MDI-20 or RMT-20
test days, and 160 mg on the RMT-10 test day. Treatment
was open label between devices (RMT vs. MDI) and
double-blind within RMT device. Patients were evaluatedfor pulmonary function (FEV1, FVC), vital signs and
adverse event until 3 h after the last dose, as described
below.
PROTOCOL
Each included patient was assigned to receive the three
study treatments (RMT-10, RMT-20, MDI-20) in random
order on three study days separated by at least 48 h. Inhaled
short-acting b2-agonists and anticholinergics were with-
drawn for 8 h prior to screening and test days, and long-
acting b2-agonists and anticholinergics were withdrawn for
48 and 12 h, respectively. Appropriate washout periods
were also applied for excluded oral medications. Lung
function measurements were performed at baseline then
45+5 min after each dose, plus 60, 90, 120 and 180 min
after the last inhalation. Baseline measurements were
performed between 07:00 and 10:00 hours, at the same
time on each study day +30 min for each patient, and the
test day proceeded only if baseline FEV1 values were within
+20% of the value obtained for that patient on the first test
day patients who showed greater FEV1 variability on three
consecutive days were to be withdrawn and replaced.
Patients were asked to avoid strenuous exercise over the
12 h preceding lung function measurements and were not
allowed cigarettes, xanthine-containing food or beverages,
or exposure to cold, smoke, dust or smells from 12 h before
the baseline measurement until the end of the last
measurement on each test day.
The primary endpoint was the increase from baseline
in the average FEV1 (measured in litres) between 45 and
245 min after the first inhalation. This was calculated by
taking the mean of the FEV1 increases recorded at 45, 95,
145, 195 and 245 min. Secondary endpoints were: (a) the
FEV1 increase (l) from baseline to 45 min after first
inhalation; (b) the FEV1 increase (l) from baseline between
60 and 180 min after the last intake (i.e. at 260–380 min);
and (c) the increases from baseline in FEV1 (%) and FVC
(l) at each time point.
Together with lung function tests, vital signs (pulse rate
and blood pressure) were measured at pre-dose and then
approximately 45 min after each dose step immediately
before spirometry on each test day. On the inclusion day
and on the final test day, patients also underwent
laboratory tests, including measurement of biochemical
parameters (potassium, creatinine, serum glutamic oxaloa-
cetic acid transaminase, serum glutamic pyruvic transami-
nase, alkaline phosphatases, g-glutamyl aminotranferase,
total bilirubin), a complete blood analysis (haemoglobin,
haematocrit, full blood count, platelet count) and theophyl-
line levels. In cases of theophylline levels being higher than
5 mg/ml, the screening visit had to be repeated. A 12-lead
resting ECG was taken at 0 and 270 min on each test day.
Rhythm strips were analysed in terms of heart rate and
QTc. All adverse events were recorded, with particular
attention paid to cough, wheeze and paradoxical
bronchospasm. Paradoxical bronchospasm was defined
as a 15% fall in FEV1 below baseline and/or the need for
rescue medication, and/or spontaneous reporting by the
FIG 1. Mean increase in FEV1 from baseline following
treatment with ipratropium bromide 10 or 20 mg/pu
administered via Respimat (RMT-10, RMT-20) or MDI
(MDI-20) (per-protocol dataset, n=36). (~)RMT-10;
(*)RMT-20, (&)MDI-20.
TABLE 1. Demographics and baseline characteristics of
included patients (n=36)
Characteristic Mean SD
Age (years) 52 6
Male/female (n) 29/7
Duration of COPD (months) 10 22
Height (cm) 173 8
Weight (kg) 72 15
FEV1 (% predicted) 526 89
FVC (% predicted) 721 106
FEV1/FVC (%) 594 77
FEV1 (l) 18 04
FVC (l) 30 06
FEV1 reversibility (%)* 307 77
*Change in FEV1 measured 60 min after inhaling two pus
of 20 mg ipratropium bromide via MDI.
492 P. IACONO ET AL.patient of any event indicative of bronchospasm within 45
min of inhaling test medication.
STATISTICAL ANALYSIS
To demonstrate therapeutic equivalence between RMT and
MDI, a null hypothesis was proposed that FEV1 measured
45–245 min after the first inhalation dose would dier by
more than 012 l between the two treatment administra-
tions. Thirty-six patients were required in this trial for an
FEV1 equivalence region of +012 l.
Least square means were obtained for per-protocol data
using analysis of variance (ANOVA). Three factors
(patients, treatment and period) were included in ANOVA,
fitted as a main eect. This model was used to analyse FEV1
(45–245 min). The test-day, pre-dose FEV1 was subtracted
prior to analysis, in order to reduce the variance. ANOVA
was used to compare the average treatment eect for each
RMT treatment vs. MDI and to obtain 95% confidence
intervals (CI) for the dierence between treatments. The
least squares means for each time point were obtained by
performing a separate ANOVA at each time point using the
model described above. These least square means were
plotted against time for each treatment. The primary
analysis described for FEV1 (45–245 min) was repeated
for FEV1 (260–380 min). To correct for time dierences,
significance levels were adjusted using retrospective powers
calculated for equivalence within a sample size of 36
patients.
Adjusted mean changes in blood pressure and pulse rate
from baseline (test-day, pre-dose) were calculated for each
treatment (using ANOVA at each time point as described
above).
Baseline data are presented as mean +SD, and result as
mean +SE. A P-value of less than 005 was considered
statistically significant.
Results
PATIENTS
Thirty-eight patients were randomized, and 36 received all
three test treatments. One patient developed acute severe
bronchitis 2 days after the first day (treated with antibiotics)
and was excluded from all ecacy analyses. Another
patient with a history of arrhythmia (treated with
disopyramide 200 mg) was withdrawn before the third test
day due to abnormal ECG, and was excluded from the per-
protocol ecacy analysis but was included in the intent-to-
treat analysis. Baseline characteristics (Table 1) and per-
protocol ecacy data are therefore presented for the 36
patients (29 male, seven female) who completed the study.
The mean duration of COPD in these patients was 10
months (mean FEV1 175 l, corresponding to 526% of the
predicted value). The patients exhibited significantly
reversible COPD (mean change in FEV1 was 307%
measured 60 min after inhaling two pus of 20 mg
ipratropium bromide via MDI; Table 1).PULMONARY FUNCTION
All ipratropium treatments produced a marked improve-
ment in FEV1 over baseline values (Fig. 1). The FEV1 vs.
time curves for both ipratropium doses administered via
RMT were similar, exhibiting a rapid onset of action,
followed by a further increase in bronchodilation with
successive inhalations until a maximal or plateau FEV1
level was achieved. The bronchodilator eect remained
substantial at the last observation time, 3 h after the final
inhalation dose, for the three treatments. Analysis of the
bronchodilation curve shows that a similar bronchodilation
(19%) was obtained 45 min after single pu of either RMT-
10 or RMT -20, and the plateau was reached after two pus
of RMT-10 or RMT-20. For MDI-20, the bronchodilation
curve was more shallow, a plateau FEV1 response being
FIG 2. Number of patients with clinically significant
changes in blood pressure and heart rate (all evaluable
patients, n=37). ( )RMT-10; (&)RMT-20, (&)MDI-20.
TABLE 2. Mean changes in heart rate and QTc from pre-
dose to 270 min in evaluable patients (n=37)
Heart rate (beats/min) QTc(ms)
Treatment Mean SE Mean SE
RMT-10 7576 73 7443 137
RMT-20 7536 90 7192 124
RMT-20 7678 93 7230 165
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(Fig. 1). Thus, maximal FEV1 values (adjusted mean
change from baseline 046, 049 and 049 l) were first
observed at 260, 245 and 245 min for MDI-20, RMT-10
and RMT-20 treatments, respectively.
Ipratropium inhalation produced adjusted mean +SE
increases in FEV1 at 45–245min of 044+002 l,
043+002 l and 036+002 l for RMT-10, RMT-20 and
MDI-20 treatments, respectively. The increase in FEV1 at
45–245 min was significantly higher for RMT-10 than
MDI-20 treatment, even though the dose was half that
delivered by MDI, with a mean treatment dierence of
0080 l (95% CI 0020–0140 l, P5001). In addition, there
was a significant dierence between RMT-20 and MDI-20
treatments, both delivering a cumulative dose of 320 mg; the
mean treatment dierence for the average change in FEV1
at 45–245 min was 0076 l (95% CI 0016–0136 l, P=001).
The bronchodilator eect of the 320 mg cumulative dose
delivered via RMT was similar to that of 160 mg via RMT.
Similar results were obtained for the intent-to-treat dataset
(n=37), with an overall significant treatment dierence for
the increase in FEV1 at 45–245 min (P=0017), and greater
bronchodilation with RMT-10 or RMT-20 than MDI-20
(P=001 and 002, respectively).
The improved bronchodilatory ecacy was confirmed
when evaluating the secondary endpoints of FEV1 ex-
pressed as the average percentage increase from baseline
values, and the average increase in FVC between 45 and
245 min. The adjusted average FVC at 45–245min in the
per-protocol group increased from pre-dose by a mean
(+SE) of 05+003, 05+003 and 04+003 l with RMT-
10, RMT-20 and MDI-20 treatments, respectively, demon-
strating a clear parallelism with the changes in FEV1. In
addition, all ipratropium treatments showed persistence of
the FEV1 increase over the 3 h following the last inhalation;
the mean +SE change in FEV1 at 260–380min was
042+002, 043+002 and 041+002 l for RMT-10,
RMT-20 and MDI-20 treatments, respectively. Average
changes in FEV1 from pre-dose at 260–380 min with RMT-
10 and RMT-20 treatments were significantly equivalent to
those for MDI-20. This was again supported by the mean
+SE changes in FVC at 260–280 min, which were 05+004
l for all three treatments.
ADVERSE EVENTS
All patients were included in the safety analysis: 37 had
received RMT-10, 36 RMT-20 and 38 MDI-20. A total of
12 adverse events (none serious) were reported by 10
patients (26%); one, seven, two and two patients suered
adverse events on RMT-10, RMT-20 and MDI-20 days and
during the between-treatment washout, respectively. The
most frequently reported adverse events were mild to
moderate headache (five reports, none considered to be
drug-related, some requiring paracetamol or acetylsalicylic
acid treatment) and pharyngeal irritation (three reports,
considered to be treatment-related). Other events (one case
each of vomiting, oesophagitis, bronchitis and abnormal
ECG: left bundle branch block) were not considered to berelated to treatment. The number of patients with clinically
significant changes in vital signs was low and balanced
across the three treatments (Fig. 2). No prominent changes
occurred on physical examination or in laboratory screens;
there was no clinical reason why these parameters should
change, but their measurement allowed a monitoring of
patient well-being. Similarly, no drug-related eects were
obtained on ECG: only very slight reductions in heart rate
and QTc were observed, and these eects were similar
within the three treatment groups (Table 2). No subject
showed any evidence of paradoxical bronchoconstriction.
Discussion
The results of our study confirm the safety and ecacy of
ipratropium bromide administered via RMT. Between
45min after initial drug inhalation and 45 min after the
final dose, greater bronchodilatory eect was obtained from
half the cumulative dose of ipratropium (RMT 10 mg per
pu) when compared with the MDI (20 mg per pu)
(P5001). Bronchodilatory responses to cumulative doses
of ipratropium given via RMT were, on average, higher
than those produced via MDI administration. Further-
more, bronchodilation produced by ipratropium delivered
via RMT was both rapid and sustained for the duration of
the study; the plateau response was reached after only two
pus, delivering a cumulative dose of 20 or 40 mg, and was
well maintained at 380 min (Fig. 1).
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reported with RMT therapy for asthma and COPD
patients. In a pilot study, Maesen et al. studied cumulative
doses of ipratropium given to 10 COPD patients via MDI
compared with two prototype SMI devices diering in
nozzle configuration and emitted particle characteristics
(17). Although bronchodilation did not dier significantly
between the three treatments, their results showed a trend
for better ecacy, with the prototype SMI exhibiting the
greatest proportion of fine particles.
RMT produces a particularly fine aerosol, with a high
‘fine particle fraction’ (6,7), which means that aerosol
droplets are capable of surviving filtration and impaction
mechanisms to achieve deposition in the lungs. Further-
more, the aerosol is emitted slowly from RMT: the particle
velocity of 10 ms71 is approximately five times slower than
that from CFC-MDIs (6,7), which reduces the potential for
drug impaction in the oropharynx.
Scintigraphic studies have confirmed that superior in
vitro particle characteristics (the result of a sophisticated
nozzle design) lead to improved lung deposition in vivo (8–
14). These studies showed that lung deposition of radi-
olabelled drug in healthy volunteers inhaling fenoterol or
flunisolide via RMT was typically twice that delivered by
MDI or MDI plus spacer, while oropharyngeal deposition
was reduced. The authors concluded that a reduction in
particle size and velocity leads to an improved deposition
pattern in the respiratory tract, which could result in
enhanced ecacy.
More recently, a series of studies have demonstrated the
safety and superior performance of the SMI device, RMT,
delivering the b2-adrenergic agonist fenoterol, or fenoterol
plus ipratropium bromide, in asthmatic patients (18–20). As
observed in our patients, a rapid onset of eect and similar
degree of bronchodilation was achieved at a half the drug
dose when administered via RMT compared with MDI,
and there were no safety concerns based on adverse events,
vital signs or ECG at doses demonstrating therapeutic
equivalence.
The results obtained with MDI administration in our
study are consistent with those observed in other cumula-
tive dose studies with ipratropium in comparable popula-
tions of COPD patients (23–25). The FEV1 time profiles
and standard deviations agreed closely with those observed
using the MDI in our study, validating the use of the MDI
group as a positive control group. The patients included in
the present study were newly diagnosed with mild to
moderate COPD, and were responsive to ipratropium
bromide. As a result, large improvements were obtained
in lung function following ipratropium inhalation, demon-
strated by changes in FEV1 and supported by those in FVC
and allowing wide comparability with other studies,
including those evaluating dierent devices or disease
states.
The cumulative-dose model which was applied allowed
us to study the eects of a high number of inhalations,
resembling the type of administration possible for a patient
with COPD suering from an acute exacerbation. Even at
the high doses administered, and the increased lung
deposition and greater bronchodilation exhibited byRMT, the ipratropium safety profiles were similar to that
of the marketed MDI. This profile is in agreement with the
previous studies in asthmatic patients, which demonstrated
a similar tolerability for treatments delivered via RMT
compared with two-fold higher doses delivered via MDI.
Indeed, Vincken et al. revealed a slightly lower incidence of
tremor and decreases in serum potassium with fenoterol
from RMT delivering 50 mg/pu than from the MDI
delivering 100 mg/pu (20).
In conclusion, our data indicate that ipratropium
bromide has a comparable safety profile when administered
either via RMT or MDI. Our results showed no consistent
clinically relevant eects on pulse rate or blood pressure, no
prominent changes on physical examination or in labora-
tory screens, and no drug-related eect on ECG. On acute
administration in patients with COPD, ipratropium bro-
mide delivered by RMT can produce more eective
bronchodilation than the MDI. Hence, RMT may be a
useful alternative to MDIs for the administration of
bronchodilator and anti-inflammatory agents in the ther-
apy of asthma and COPD. Furthermore, the improved lung
targeting by RMT may permit treatment with a lower daily
drug dose than inhalation via MDI.
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